Related Experiment Video
Updated: Jul 16, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
RIPTACs: A groundbreaking approach to drug discovery
Zonghui Ma1, Andrew A Bolinger1, Jia Zhou1
1Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, USA.
Abstract:
Regulated induced proximity targeting chimeras (RIPTACs), a new class of heterobifunctional molecules, show promise in specifically targeting and eliminating cancer cells while leaving healthy cells unharmed. As a groundbreaking drug discovery approach, RIPTACs work by forming a stable complex with two proteins, one specifically found in cancer cells (target protein, TP) and the other pan-essential for cell survival (effector protein, EP), selectively disrupting the function of the EP in cancer cells and causing cell death. Interestingly, the TPs need not be linked to disease progression, broadening the spectrum of potential drug targets. This review summarizes the discovery and recent advances of the RIPTAC strategy. Additionally, it discusses the associated opportunities and challenges as well as future perspectives in this field.
Insights
Regulated induced proximity targeting chimeras (RIPTACs) offer a novel approach to cancer therapy by selectively eliminating cancer cells. This groundbreaking strategy targets cancer-specific proteins to disrupt essential cell functions, leading to cancer cell death.
Area of Science:
- Drug discovery and development
- Molecular oncology
- Biotechnology
Background:
- Regulated induced proximity targeting chimeras (RIPTACs) are emerging heterobifunctional molecules.
- RIPTACs selectively target cancer cells by forming complexes with cancer-specific target proteins (TPs) and essential effector proteins (EPs).
Purpose of the Study:
- To review the discovery and recent advancements in RIPTAC technology.
- To discuss the opportunities and challenges associated with RIPTAC-based cancer therapies.
- To explore future perspectives in the field of RIPTACs.
Main Methods:
- This review summarizes existing literature on RIPTACs.
- It analyzes the mechanism of action for RIPTACs in cancer cell elimination.
- The review discusses the potential for targeting a broad range of cancer types.
Main Results:
- RIPTACs demonstrate a promising strategy for cancer cell-specific elimination.
- The mechanism involves targeted disruption of effector proteins essential for cell survival.
- TPs do not require a direct link to disease progression, expanding therapeutic targets.
Conclusions:
- RIPTACs represent a groundbreaking approach in cancer drug discovery.
- This strategy offers a method for selective cancer cell killing with minimal harm to healthy cells.
- Further research and development hold significant promise for RIPTACs in oncology.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
00:05A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
Related Concept Videos
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Patch Clamp
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...